<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01765023</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_ATM_101</org_study_id>
    <nct_id>NCT01765023</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Interactions Between Atorvastatin and Metformin in Healthy Male Subjects</brief_title>
  <official_title>An Open-label, Fixed-sequence Study to Evaluate Pharmacokinetic Interactions Between Atorvastatin and Metformin in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the pharmacokinetic interactions between atorvastatin
      and metformin single or co-administered in healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Evaluate PK interaction of atorvastatin and metformin</measure>
    <time_frame>Throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Evaluate PK interaction of 2-OH-atorvastatin and metformin</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single administration : atorvastatin 40mg, qd, 7days(oral) combination administration : atorvastatin 40mg and metformin XR 1000mg, qd, 7days(oral)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single administration : metformin XR 1000mg, qd, 7days(oral) combination administration : atorvastatin 40mg and metformin XR 1000mg, qd, 7days(oral)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Period I : atorvastatin, Period II : atorvastatin and metformin</intervention_name>
    <arm_group_label>Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Period I : metformin, Period II : atorvastatin and metformin</intervention_name>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willing to adhere to protocol requirements and sign a informed consent form

          2. Healthy male volunteers who are in age range of 20-55 years and the weight range is
             not exceed Â±20% of ideal weight. Ideal weight = [height -100]*0.9

          3. Subjects with no history of any significant chronic disease

          4. Judged to be in good health on the basis of their vital sign, ECG, physical exam and
             routine laboratory data for this trial by investigators

        Exclusion Criteria:

          1. Subjects taking inducer or inhibitor of drug metabolism enzyme such as barbital within
             28days prior to study medication dosing

          2. Subjects with Symptoms of acute disease within 28days prior to study medication dosing

          3. Subjects with a history of gastrointestinal diseases which might significantly change
             ADME of medicines

          4. Subjects with a history of abdominal surgery within food and water limit

          5. Subjects with a history of clinically significant allergies including drug allergies

          6. Subjects with anaphylaxis to atorvastatin and/or metformin

          7. Subjects with a history or plan iodine radiotherapy within 28 days prior to drug
             administration

          8. Subjects with a history of myopathy

          9. Subjects with a hereditary problems, for example, galactose intolerance, Lapp lactase
             deficiency or glucose-galactose malabsorption

         10. Clinical laboratory test values are outside the accepted normal range

               -  AST or ALT &gt;1.25 times to normal range

               -  Total bilirubin &gt;1.5 times to normal range

               -  Creatinine clearance &lt;90 mL/min

         11. Subjects with a history of drug, caffeine and alcohol abuse(caffeine &gt; 5cups/day,
             cigarette &gt; 10/day, alcohol &gt; 30g/day) or have ever drank within 7 days prior to drug
             administration

         12. Special diet known to interfere with the absorption, distribution, metabolism or
             excretion of drugs (especially, consumption of grapefruit juice) within 7 days prior
             to drug administration

         13. Donated blood within 60 days prior to dosing

         14. Participated in a previous clinical trial within 60 days prior to dosing

         15. Subjects who have received any drugs that might confound the results of the trial
             based on medical judgement by investigators within 10days prior to drug administration

         16. Subjects considered as unsuitable based on medical judgement by investigators
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Inje University Pusan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2012</study_first_submitted>
  <study_first_submitted_qc>January 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2013</study_first_posted>
  <last_update_submitted>April 7, 2013</last_update_submitted>
  <last_update_submitted_qc>April 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

